Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program FDAThe U.S.RegulatoryRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) FDA The U.S. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ambrosia adds a megaround for obesity drugsNext: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
